WaveMan
WaveMan · Company
BBLG · Bone Biologics Corp
> Search tickers & screens ⌘K
LIVE
← All companies

BBLG Bone Biologics (BBLG) Insider Trading, Ownership & Congress Trades

Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001419554
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
2
13F, latest reported quarter

Bone Biologics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Bone Biologics Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Walsh Deina H
Chief Financial Officer
BUY
2023-09-14 SECtraded 2023-09-13
8,000
$5.1K
-98.9%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 6, 2023.
  • The trade is 53.3% of the 15,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Walsh Deina H bought about $5.1K of BBLG on Sep 13, 2023; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
Frelick Jeff
Chief Executive Officer
BUY
2023-09-12 SECtraded 2023-09-11
9,500
$6.6K
-98.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 31, 2023.
  • The trade is 55.2% of the 17,204 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Frelick Jeff bought about $6.6K of BBLG on Sep 11, 2023, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
Walsh Deina H
Chief Financial Officer
BUY
2023-09-07 SECtraded 2023-09-06
6,700
$4.8K
-98.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 95.7% of the 7,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Walsh Deina H bought about $4.8K of BBLG on Sep 6, 2023; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
Walsh Deina H
Chief Financial Officer
BUY
2023-09-07 SECtraded 2023-09-06
300
$210
-98.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 300 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Walsh Deina H bought about $210 of BBLG on Sep 6, 2023; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
Frelick Jeff
Chief Executive Officer
BUY
2023-09-05 SECtraded 2023-08-31
7,600
$5.0K
-98.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 98.7% of the 7,704 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Frelick Jeff bought about $5.0K of BBLG on Aug 31, 2023, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
2 funds bought in last quarter
Revenue
+0.0% year over year
below 78% of Medical Devices
Margin
-0.3% net margin
more than 67% of Medical Devices
Buybacks
no share repurchases reported
Short interest
0.8% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 73% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BBLG

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-83.3%12M
-83%-55%-27%+1%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BBLG: institutional holders (13F)

13F holdings, latest reported quarter
CITADEL ADVISORS LLC
50,277 sh
$428.7K
UBS Group AG
513 sh
$4.1K
Tower Research Capital LLC (TRC)
1,953 sh
$2.7K
SBI Securities Co., Ltd.
230 sh
$315

Congress trades in BBLG

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BBLG planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BBLG mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$10.3K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$866 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Not applicable
1 active
What changed recently
Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis
2026-10-16 · Completion moved 2025-06-01 → 2026-12-31
Not applicable
Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis
2026-10-16 · Unknown → Recruiting
Not applicable
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Mr. Frelick
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$426.3K
$430.8K
$263.1K
n/a
n/a
2024
$384.9K
$405.7K
$242.4K
n/a
n/a
2023
$376.6K
$333.0K
$238.3K
n/a
n/a
2022
$414.7K
$406.8K
$250.5K
-96%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 2 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

BBLG financials

Revenue growth
0.0%
XBRL, annual
Net margin
-0.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.1B
four quarters, 2020-07-01 to 2021-06-30
Net margin, TTM
-0.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-55.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-50.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-58.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$3.2M-$4.2M-$9.4M-$3.7M
Net income-$3.1M-$4.1M-$8.9M-$1.5M
EPS (diluted)-2.65-28.96-34.01-31.15
Operating cash flow-$2.7M-$4.1M-$9.6M-$3.6M
Cashn/an/an/a$7.5M
SEC XBRL, fiscal years, as known on 2026-10-28

BBLG Stock Sonar score 3/7 axes

Find similar shapesCompare

BBLG ranks highest on risk and compliance (92nd percentile) and profitability (32nd), and lowest on growth (22nd), among Medical Devices peers.

Profitability
32
Inputs
  • Return on equity-55.0% · 36 pct, sector of 183
  • Return on assets-50.5% · 30 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-58.2% · 29 pct, sector of 188
Growth
22
Inputs
  • Revenue growth, YoY+0.0% · 22 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
92
Inputs
  • Short interest, % of float+0.8% · 79 pct, sector of 241
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+1.5% · 96 pct, sector of 198
4 not measured: Financial health, Insider conviction, Institutional and government, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies